Abstract
This article follows a research peptide from synthesis through purification, lyophilisation, filling, and analysis, to the Certificate of Analysis that documents it, showing where each reported value originates.
A Certificate of Analysis is often the only part of a peptide's production history a researcher sees. Reading it well is easier with some knowledge of the sequence that produced it, because each figure on the document corresponds to a specific stage and carries the limitations of that stage.
Synthesis
Most research peptides are made by solid phase peptide synthesis. The chain is assembled one residue at a time on an insoluble resin support: an incoming amino acid is coupled to the growing chain, a protecting group is removed to expose the next reaction site, and the cycle repeats. Building on a solid support allows excess reagents and by-products to be washed away between steps.
Where impurities originate
No coupling step is perfectly complete. A step that falls slightly short leaves a fraction of chains missing that residue, producing a deletion sequence that persists through the remainder of the synthesis. Incomplete removal of protecting groups, and side reactions during the final cleavage from the resin, add further related substances. Because these products closely resemble the target, they are the impurities most demanding to separate and the reason chromatographic resolution matters so much later.
Cleavage and purification
Once the sequence is complete, the peptide is cleaved from the resin and the remaining side chain protecting groups are removed. The crude material is then purified, typically by preparative reversed-phase HPLC: the mixture passes through a column, components separate, and fractions are collected across the eluting main peak.
Fraction selection is a deliberate trade-off. Collecting narrowly around the peak centre yields higher purity and less material; collecting more broadly yields more material and admits more closely related substances. Selected fractions are analysed, pooled, and carried forward.
Lyophilisation
The purified solution is freeze-dried. The material is frozen and water is removed by sublimation under reduced pressure, leaving a dry, porous cake. Lyophilisation improves stability substantially, because most degradation routes require water. It also leaves characteristic residues: counter-ions from the acidic mobile phase used in purification, a small amount of residual water, and possibly traces of organic solvent. These form part of the powder's mass without being part of the peptide, which is why peptide content is measured separately from chromatographic purity.
The powder in a vial is the peptide plus what purification and drying left behind. Documentation should let a reader see both.
Filling and batch definition
Dried material is filled into individual vials, sealed, and labelled. At this point the batch becomes a defined entity: a quantity produced under uniform conditions, assigned a unique identifier that appears on every container and on all associated records. Everything reported subsequently attaches to that identifier rather than to the product name.
Analytical testing
A representative sample is drawn and prepared for analysis. Two core determinations follow, addressing separate questions.
- Identity by mass spectrometry, comparing the observed mass with the theoretical mass for the sequence
- Purity by high performance liquid chromatography, reported as the relative area of the main peak
- Where applicable, peptide content by mass, and water or residual solvent determinations
Independent testing
Testing may be performed in-house, by an external laboratory, or both. External analysis separates the party producing the material from the party measuring it, and where the laboratory maintains its own verification record, a document can be confirmed at source rather than taken on the supplier's word.
The certificate itself
The COA assembles these results into a single reviewable record: compound identity, batch identifier, quantity analysed, methods and their conditions, numerical results, analysis date, and the testing laboratory. Where chromatograms and spectra are included, the reader can assess how each figure was obtained rather than only what it states.
Reading the certificate against the process makes its scope clear. It reports measurements on one sample drawn from one batch on one date. It says nothing about a different batch, and it describes the material's condition at that moment rather than after months of storage. Within those limits it is the strongest available link between a written specification and the vial on the bench.
Key takeaways
- Solid phase synthesis inevitably produces closely related impurities that purification must separate
- Fraction collection during purification trades yield against purity
- Lyophilisation leaves counter-ions and residual water, so peptide content differs from chromatographic purity
- Filling defines the batch, and the batch identifier ties every record together
- A COA reports one sample, one batch, one date, and independent testing strengthens it
